(Q39455887)

English

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

Ulrich Keilholz

2

object named as

Ulrich Keilholz

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Birgit Hotz

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Alberto Fusi

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Heinz J Buhr

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hubert G Hotz

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

20 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

252-264

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

https://scigraph.springernature.com/pub.10.1007/s10120-011-0102-9

0 references

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Cetuximab, its clinical use and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

An orthotopic nude mouse model for preclinical research of gastric cardia cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

An Orthotopic Nude Mouse Model for Evaluating Pathophysiology and Therapy of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1007%2FS10120-011-0102-9

21 January 2018

Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastric cancer: epidemiology, pathology and treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22011788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10120-011-0102-9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

release_kfbcaxgnt5bgdbgtwn45etx7ka

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39455887&oldid=1829129900"